These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23519576)

  • 21. Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study.
    Ilic K; Song I; Wu J; Martin P
    Clin Transl Sci; 2020 Nov; 13(6):1260-1270. PubMed ID: 32506738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
    Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
    J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
    Donado E; Izquierdo I; Pérez I; García O; Antonijoan RM; Gich I; Solans A; Peña J; Morganroth J; Barbanoj MJ
    Br J Clin Pharmacol; 2010 Apr; 69(4):401-10. PubMed ID: 20406224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.
    Green CL; Whellan DJ; Lambe L; Bellibas SE; Wijngaard P; Prats J; Krucoff MW
    J Cardiovasc Pharmacol; 2013 Nov; 62(5):466-78. PubMed ID: 23921301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
    Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
    Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.
    Darpo B; Ferber G; Zhou M; Sumeray M; Sager P
    Ann Noninvasive Electrocardiol; 2013 Nov; 18(6):577-89. PubMed ID: 24118671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study.
    Kim S; Lee H; Ko JW; Kim JR
    Clin Ther; 2019 Nov; 41(11):2204-2218. PubMed ID: 31564512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thorough QT/QTc Evaluation of the Cardiac Safety of Enarodustat (JTZ-951), an Oral Erythropoiesis-Stimulating Agent, in Healthy Adults.
    Pai SM; Yamada H; Kleiman RB; Zhuo R; Huang QM; Koretomo R
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):884-898. PubMed ID: 34159762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of therapeutic and supratherapeutic oral doses of nomegestrol acetate (NOMAC)/17β-estradiol (E2) on QTcF intervals in healthy women: results from a randomized, double-blind, placebo- and positive-controlled trial.
    de Kam PJ; van Kuijk J; Lillin O; Post T; Thomsen T
    Clin Drug Investig; 2014 Jun; 34(6):413-20. PubMed ID: 24777591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
    Taubel J; Naseem A; Harada T; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2010 Apr; 69(4):391-400. PubMed ID: 20406223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
    Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
    Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study.
    Mendzelevski B; Ausma J; Chanter DO; Robinson P; Kerstens R; Vandeplassche L; Camm J
    Br J Clin Pharmacol; 2012 Feb; 73(2):203-9. PubMed ID: 21848574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intravenous zanamivir on cardiac repolarization.
    Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
    Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.
    Chen N; Ye Y; Liu L; Reyes J; Assaf MS; Kasserra C; Zhou S; Palmisano M
    Basic Clin Pharmacol Toxicol; 2013 Sep; 113(3):179-86. PubMed ID: 23639045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.
    Garza R; Huo MH
    Expert Rev Cardiovasc Ther; 2012 Apr; 10(4):423-7. PubMed ID: 22458575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
    Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
    Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
    Schilling U; Henrich A; Muehlan C; Krause A; Dingemanse J; Ufer M
    Clin Drug Investig; 2021 Aug; 41(8):711-721. PubMed ID: 34331678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
    Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.